Iloprost (Ventavis)

Subscribe to Selected New Research on Iloprost

689 relevant articles (112 outcomes, 124 trials/studies) found for this Drug

Description: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.

Also Known As:

Ventavis; CoTherix Brand of Iloprost; ZK-36374; ZK 36374; ZK36374; Ciloprost; Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-

Relationship Network

Drug Context: Research Results

Lipids: 13315

Fatty Acids: 4660

Unsaturated Fatty Acids: 2221

Eicosanoids: 1153

Prostaglandins: 6156

Synthetic Prostaglandins: 156

Iloprost: 689

eptaloprost: 1

iloprost phenacyl ester: 1

2,6-dichloro-4-aminophenol iloprost

Biological Factors: 868

Inflammation Mediators: 485

Synthetic Prostaglandins: 156

Iloprost: 689

eptaloprost: 1

iloprost phenacyl ester: 1

2,6-dichloro-4-aminophenol iloprost

Experts

1.	Seeger, Werner: 12 articles (07/2008 - 04/2002)
2.	Grimminger, Friedrich: 10 articles (07/2008 - 04/2002)
3.	Weissmann, Norbert: 10 articles (07/2008 - 04/2002)
4.	Seeger, W: 8 articles (02/2004 - 01/2000)
5.	Ghofrani, Hossein Ardeschir: 7 articles (07/2008 - 04/2002)
6.	Schermuly, Ralph Theo: 7 articles (07/2008 - 04/2002)
7.	Hoeper, M M: 7 articles (12/2007 - 01/2000)
8.	Olschewski, Horst: 7 articles (01/2007 - 04/2002)
9.	Ghofrani, H A: 7 articles (02/2004 - 01/2000)
10.	Wilkens, H: 6 articles (10/2006 - 01/2000)

Related Diseases

1.	Pulmonary Hypertension (Ayerza Syndrome) 01/01/2004 - "While inhaled iloprost has been described to be highly effective in the treatment of primary pulmonary hypertension, the possibility of contrary "paradoxical" reactions in isolated patients is emphasised, with a dramatic increase of PVR and a possible adverse outcome." 03/01/2008 - "In a randomized, double-blind, placebo controlled, multicenter study in 203 patients with pulmonary hypertension inhaled iloprost showed significant improvement of exercise capacity and pulmonary hemodynamics with excellent tolerability and safety" 01/01/2004 - "Inhaled iloprost 2.5 or 5 microg six or nine times daily for 12 weeks (n = 101) significantly (p < 0.01) improved a combined clinical endpoint of a > or =10% increase in distance walked in 6 minutes and an improvement of > or =1 class in New York Heart Association functional class without clinical deterioration or death (16.8 versus 4.9% of placebo recipients, n = 102) in patients with severe PPH or selected forms of nonprimary pulmonary hypertension" 02/01/2004 - "The main objective of the present study was to evaluate the safety and efficacy of inhaled iloprost in HIV-related pulmonary hypertension" 07/15/2008 - "RATIONALE: Iloprost is effective for the treatment of pulmonary hypertension" Get all the results and reference details, order at left...
2.	Ischemia 03/01/2002 - "BACKGROUND: Iloprost given in a standard dose regimen (0.5-2 ng/kg/min for 6 hours daily over 21-28 days) has proven to be effective and safe in hospitalized patients with critical limb ischemia" 01/01/2005 - "Iloprost has been found to be effective in attenuating ischemia reperfusion-induced remote organ damage, in this case, lung injury, in rats." 09/01/2006 - "Recently, iloprost has been shown to be safe and effective in critical limb ischemia patients when administered per 7 days" 11/01/2008 - "Iloprost infusion for 72 hr after open AAA repair was associated with improved systemic perfusion and decreased systemic ischemia" 04/01/1996 - "Iloprost (12 nm/l) inhibited the release of TXA2 and improved the recovery of cardiac hemodynamics after ischemia" Get all the results and reference details, order at left...
3.	Ulcer 09/01/2008 - "CONCLUSION: Low-dose iloprost was shown to be equally effective as high-dose iloprost in longterm treatment and was very effective in therapy of digital ulcers" 09/01/2003 - "In three different studies, iloprost given for 5 days in the highest tolerated dose of 1-2 ng/kg/min provided a significant improvement of the disease measured by the number and intensity of Raynaud attacks, healing of digital ulcers, and digital perfusion" 01/01/1994 - "This study failed to show any statistically significant reduction in the ulcer size as a result of the iloprost treatment compared to the placebo treatment" 03/15/2007 - "g., iloprost, can be recommended as first-line treatment of ischemic digital ulcers" 01/01/2000 - "REVIEWER'S CONCLUSIONS: Intravenous Iloprost is effective in the treatment of Raynaud's phenomenon secondary to scleroderma at decreasing the frequency and severity of attacks and preventing or healing digital ulcers" Get all the results and reference details, order at left...
4.	Hypertension (High Blood Pressure) 05/01/2008 - "Inhaled iloprost is an effective treatment for NYHA class III pulmonary arterial hypertension, either idiopathic primary or associated with a particular condition, such as scleroderma" 09/01/2005 - "AIMS: To describe the long-term clinical efficacy of inhaled iloprost as first-line vasodilator mono-therapy in patients with idiopathic pulmonary arterial hypertension (IPAH)" 01/15/2008 - "OBJECTIVES: This study investigated the short- and long-term outcome of children with pulmonary arterial hypertension (PAH) treated with inhaled iloprost" 09/01/2007 - "However, no cases of severe pulmonary arterial hypertension were observed in the patients treated with iloprost, suggesting that studies focusing on the possible preventive action of iloprost on the progression of SSc- associated mild pulmonary arterial hypertension would be warranted." 07/01/2005 - "OBJECTIVE: To review the pharmacology, pharmacodynamics, and clinical trials evaluating inhaled iloprost in pulmonary arterial hypertension (PAH)" Get all the results and reference details, order at left...
5.	Systemic Scleroderma (Systemic Sclerosis) 05/01/2006 - "CONCLUSION: Hepatic perfusion significantly improved after Iloprost administration, suggesting that such treatment might be useful in preventing vascular complications in patients with systemic sclerosis" 09/01/1998 - "CONCLUSION: The results on the daily duration of Raynaud's attacks suggest that both 50 and 100 microg oral iloprost twice daily may be effective in the treatment of Raynaud's phenomenon secondary to systemic sclerosis" 09/01/2008 - "Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study." 02/01/2008 - "The aim of this study is to evaluate the effect of iloprost on oxidative status in ten patients with systemic sclerosis by measuring urinary levels of 8-isoprostaglandin-F(2alpha), a member of F(2)-isoprostanes" 09/01/2003 - "Although the effect of this treatment regimen should be proven in further long-term studies, we think that an intermittent continuous therapy with iloprost could result in an improvement or stabilization of systemic sclerosis." Get all the results and reference details, order at left...
211 Diseases and 689 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Alprostadil (Muse)
3.	bosentan (Tracleer)
4.	sildenafil (Viagra)
5.	Prostaglandins
6.	Nitric Oxide (Nitrogen Monoxide)
7.	Dinoprostone (PGE2)
8.	Heparin (Liquaemin)
9.	Dextrans (Dextran)
10.	Phosphocreatine (Neoton)
333 Drugs and Important Bio-Agents and 477 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Amputation
2.	Decompression
3.	Heart Transplantation (Grafting, Heart)
4.	Lasers (Laser)
5.	Cardiopulmonary Bypass (Heart-Lung Bypass)
35 Therapies and Procedures and 69 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>